1,144,457 research outputs found
Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial
Background:
Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury. Here, we evaluated the effect of the DPP4 inhibitor sitagliptin on eMSC in women with RPL, determined the impact on endometrial decidualization, and assessed the feasibility of a full-scale clinical trial.
Methods:
A double-blind, randomised, placebo-controlled feasibility trial on women aged 18 to 42 years with a history of 3 or more miscarriages, regular menstrual cycles, and no contraindications to sitagliptin. Thirty-eight subjects were randomised to either 100 mg sitagliptin daily for 3 consecutive cycles or identical placebo capsules. Computer generated, permuted block randomisation was used to allocate treatment packs. Colony forming unit (CFU) assays were used to quantify eMSC in midluteal endometrial biopsies. The primary outcome measure was CFU counts. Secondary outcome measures were endometrial thickness, study acceptability, and first pregnancy outcome within 12 months following the study. Tissue samples were subjected to explorative investigations.
Findings:
CFU counts following sitagliptin were higher compared to placebo only when adjusted for baseline CFU counts and age (RR: 1.52, 95% CI: 1.32–1.75, P<0.01). The change in CFU count was 1.68 in the sitagliptin group and 1.08 in the placebo group. Trial recruitment, acceptability, and drug compliance were high. There were no serious adverse events. Explorative investigations showed that sitagliptin inhibits the expression of DIO2, a marker gene of senescent decidual cells.
Interpretation:
Sitagliptin increases eMSCs and decreases decidual senescence. A large-scale clinical trial evaluating the impact of preconception sitagliptin treatment on pregnancy outcome in RPL is feasible and warranted.
Funding:
Tommy's Baby Charity.
Clinical trial registration:
EU Clinical Trials Register no. 2016-001120-54
Numb Isoforms Deregulation in Medulloblastoma and Role of p66 Isoform in Cancer and Neural Stem Cells
Numb is an intracellular protein with multiple functions. The two prevalent isoforms, Numb p66 and Numb p72, are regulators of differentiation and proliferation in neuronal development. Additionally, Numb functions as cell fate determinant of stem cells and cancer stem cells and its abnormal expression has been described in several types of cancer. Involvement of deregulated Numb expression has been described in the malignant childhood brain tumor medulloblastoma, while Numb isoforms in these tumors and in cancer stem-like cells derived from them, have not been studied to date. Here we show that medulloblastoma stem-like cells and cerebellar neuronal stem cells (NSCs) express Numb p66 where its expression tampers stemness features. Furthermore, medulloblastoma samples evaluated in this study express decreased levels of Numb p66 while overexpressed Numb p72 compared with normal tissues. Our results uncover different roles for the two major Numb isoforms examined in medulloblastoma and a critical role for Numb p66 in regulating stem-like cells and NSCs maintenance
A 3D <i>in vitro</i> model reveals differences in the astrocyte response elicited by potential stem cell therapies for CNS injury.
Aim: This study aimed to develop a 3D culture model to test the extent to which transplanted stem cells modulate astrocyte reactivity, where exacerbated glial cell activation could be detrimental to CNS repair success. Materials & methods: The reactivity of rat astrocytes to bone marrow mesenchymal stem cells, neural crest stem cells (NCSCs) and differentiated adipose-derived stem cells was assessed after 5 days. Schwann cells were used as a positive control. Results: NCSCs and differentiated Schwann cell-like adipose-derived stem cells did not increase astrocyte reactivity. Highly reactive responses to bone marrow mesenchymal stem cells and Schwann cells were equivalent. Conclusion: This approach can screen therapeutic cells prior to in vivo testing, allowing cells likely to trigger a substantial astrocyte response to be identified at an early stage. NCSCs and differentiated Schwann cell-like adipose-derived stem cells may be useful in treating CNS damage without increasing astrogliosis
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population
The identification of signaling pathways that affect the cancer stem-like phenotype may provide insights into therapeutic targets for combating embryonal rhabdomyosarcoma. The aim of this study was to investigate the role of the MEK/ERK pathway in controlling the cancer stem-like phenotype using a model of rhabdospheres derived from the embryonal rhabdomyosarcoma cell line (RD)
Stem-Like Adaptive Aneuploidy and Cancer Quasispecies
We analyze and reinterpret experimental evidence from the literature to argue
for an ability of tumor cells to self-regulate their aneuploidy rate. We
conjecture that this ability is mediated by a diversification factor that
exploits molecular mechanisms common to embryo stem cells and, to a lesser
extent, adult stem cells, that is eventually reactivated in tumor cells.
Moreover, we propose a direct use of the quasispecies model to cancer cells
based on their significant genomic instability (i.e. aneuploidy rate), by
defining master sequences lengths as the sum of all copy numbers of physically
distinct whole and fragmented chromosomes. We compute an approximate error
threshold such that any aneuploidy rate larger than the threshold would lead to
a loss of fitness of a tumor population, and we confirm that highly aneuploid
cancer populations already function with aneuploidy rates close to the
estimated threshold
Chemical approaches to targeting drug resistance cancer stem cells
STEMCHEM is a COST action aiming to
target causes of drug resistance in cancer stem cells.
Cancer stem cells are cells which are believed to be responsible for the larger part of the regenerative capacity
of cancers. They are also thought to be similar to adult
stem cells in that they do not proliferate most of the time
and are thus resistant to many kinds of chemotherapy.
The action brings together labs around Europe in both
biological and chemical fields to work together in this
regard. Biologists targeting individual stem-cell related
molecules as well as stem cell phenotypes (like the un-diff erentiated state), test chemicals from numerous labs
for activity in high throughput screens, with the aim of
identifying new drug targets. This COST action, like
most others, o ffers opportunities for Malta, both in a
general way and also particularly for a small country
with small labs.peer-reviewe
Effect of Dedifferentiation on Time to Mutation Acquisition in Stem Cell-Driven Cancers
Accumulating evidence suggests that many tumors have a hierarchical
organization, with the bulk of the tumor composed of relatively differentiated
short-lived progenitor cells that are maintained by a small population of
undifferentiated long-lived cancer stem cells. It is unclear, however, whether
cancer stem cells originate from normal stem cells or from dedifferentiated
progenitor cells. To address this, we mathematically modeled the effect of
dedifferentiation on carcinogenesis. We considered a hybrid
stochastic-deterministic model of mutation accumulation in both stem cells and
progenitors, including dedifferentiation of progenitor cells to a stem
cell-like state. We performed exact computer simulations of the emergence of
tumor subpopulations with two mutations, and we derived semi-analytical
estimates for the waiting time distribution to fixation. Our results suggest
that dedifferentiation may play an important role in carcinogenesis, depending
on how stem cell homeostasis is maintained. If the stem cell population size is
held strictly constant (due to all divisions being asymmetric), we found that
dedifferentiation acts like a positive selective force in the stem cell
population and thus speeds carcinogenesis. If the stem cell population size is
allowed to vary stochastically with density-dependent reproduction rates
(allowing both symmetric and asymmetric divisions), we found that
dedifferentiation beyond a critical threshold leads to exponential growth of
the stem cell population. Thus, dedifferentiation may play a crucial role, the
common modeling assumption of constant stem cell population size may not be
adequate, and further progress in understanding carcinogenesis demands a more
detailed mechanistic understanding of stem cell homeostasis
Overexpression of Large-Conductance Calcium-Activated Potassium Channels in Human Glioblastoma Stem-Like Cells and Their Role in Cell Migration
Glioblastomas (GBMs) are brain tumors characterized by diffuse invasion of cancer cells into the healthy brain parenchyma, and establishment of secondary foci. GBM cells abundantly express large-conductance, calcium-activated potassium (BK) channels that are thought to promote cell invasion. Recent evidence suggests that the GBM high invasive potential mainly originates from a pool of stem-like cells, but the expression and function of BK channels in this cell subpopulation have not been studied. We investigated the expression of BK channels in GBM stem-like cells using electrophysiological and immunochemical techniques, and assessed their involvement in the migratory process of this important cell subpopulation. In U87-MG cells, BK channel expression and function were markedly upregulated by growth conditions that enriched the culture in GBM stem-like cells (U87-NS). Cytofluorimetric analysis further confirmed the appearance of a cell subpopulation that co-expressed high levels of BK channels and CD133, as well as other stem cell markers. A similar association was also found in cells derived from freshly resected GBM biopsies. Finally, transwell migration tests showed that U87-NS cells migration was much more sensitive to BK channel block than U87-MG cells. Our data show that BK channels are highly expressed in GBM stem-like cells, and participate to their high migratory activity. This article is protected by copyright. All rights reserved
Recommended from our members
Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells.
Tumor cells harboring stem-like/cancer stem cell (CSC) properties have been identified and isolated from numerous hematological and solid malignancies. These stem-like tumor cells can persist following conventional cytoreductive therapies, such as chemotherapy and radiotherapy, thereby repopulating the tumor and seeding relapse and/or metastasis. We have previously shown that natural killer (NK) cells preferentially target stem-like tumor cells via non- major histocompatibility complex (MHC) restricted mechanisms. Here, we demonstrated that the proteasome inhibitor, bortezomib, augments NK cell targeting of stem cell-like tumor cells against multiple solid human tumor-derived cancer lines and primary tissue samples. Mechanistically, this was mediated by the upregulation of cell surface NK ligands MHC class I chain-related protein A and B (MICA and MICB) on aldehyde dehydrogenases (ALDH)-positive CSCs. The increased expression of MICA and MICB on CSC targets thereby enhanced NK cell mediated killing in vitro and ex vivo from both human primary tumor and patient-derived xenograft samples. In vivo, the combination of bortezomib and allogeneic NK cell adoptive transfer in immunodeficient mice led to increased elimination of CSCs as well as tumor growth delay of orthotopic glioblastoma tumors. Taken together, our data support the combination bortezomib and NK transfer as a strategy for both CSC targeting and potentially improved outcomes in clinical cancer patients
Successful reprogramming of epiblast stem cells by blocking nuclear localization of β-catenin.
Epiblast stem cells (EpiSCs) in mice and rats are primed pluripotent stem cells (PSCs). They barely contribute to chimeric embryos when injected into blastocysts. Reprogramming of EpiSCs to embryonic stem cell (ESC)-like cells (rESCs) may occur in response to LIF-STAT3 signaling; however, low reprogramming efficiency hampers potential use of rESCs in generating chimeras. Here, we describe dramatic improvement of conversion efficiency from primed to naive-like PSCs through upregulation of E-cadherin in the presence of the cytokine LIF. Analysis revealed that blocking nuclear localization of β-CATENIN with small-molecule inhibitors significantly enhances reprogramming efficiency of mouse EpiSCs. Although activation of Wnt/β-catenin signals has been thought desirable for maintenance of naive PSCs, this study provides the evidence that inhibition of nuclear translocation of β-CATENIN enhances conversion of mouse EpiSCs to naive-like PSCs (rESCs). This affords better understanding of gene regulatory circuits underlying pluripotency and reprogramming of PSCs
- …